Clinical Trial

Virtual Reality and Cranial Nerve Neuromodulation to Manage Chronic Pain

Study acronym: VR & CN-NINM
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 15, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
In Canada, veterans suffer from chronic pain at twice the rate of the general population. This pain is often linked to post-traumatic stress disorder (PTSD), and both have a major impact on their quality of life. The autonomic nervous system (ANS) plays a key role in these pathologies, making its modulation a promising therapeutic target. Virtual reality (VR) is already being used to alleviate pain and PTSD in veterans, mainly by modulating ANS reactivity. Two types of VR exist: prolonged exposure (desensitization) and the calming effect, the latter being better tolerated and more suitable for rebalancing the ANS. However, its effects on pain remain modest and temporary. To reinforce these benefits, it is proposed to combine VR with a new approach called cranial nerve non-invasive neuromodulation (CN-NINM), an innovative technique that allows the generation of a direct flow of neuronal impulses via the stimulation of the tongue. The goal of this project is therefore to document the efficacy of VR and the combination of VR and CN-NINM on pain and ANS in veterans suffering from chronic pain and PTSD. VR, CN-NINM and the combination of the two will be applied for 20 minutes. Clinical pain, experimental pain and ANS reactivity will be assessed before and after the interventions. At the end of this study, it is expected that the investigators will be able to document the type of effect CN-NINM could have, and that it could become a complementary therapeutic option.
Trial Details
NCT Number NCT07065396
Lead Sponsor Université de Sherbrooke
Collaborators: Chronic Pain Center of Excellence for Canadian Veterans, Quebec Pain Research Network
Conditions Chronic Pain, PTSD - Post Traumatic Stress Disorder
Enrollment 15 participants
Start Date 2025-07
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-07-15